These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18155613)

  • 21. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
    Thakur P; Nehru B
    Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage.
    Binienda ZK; Sarkar S; Mohammed-Saeed L; Gough B; Beaudoin MA; Ali SF; Paule MG; Imam SZ
    Neurosci Lett; 2013 Apr; 541():233-7. PubMed ID: 23499956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
    Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease.
    Greene JG; Noorian AR; Srinivasan S
    Exp Neurol; 2009 Jul; 218(1):154-61. PubMed ID: 19409896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
    Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
    Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models.
    Hu LF; Lu M; Tiong CX; Dawe GS; Hu G; Bian JS
    Aging Cell; 2010 Apr; 9(2):135-46. PubMed ID: 20041858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
    Mulcahy P; Walsh S; Paucard A; Rea K; Dowd E
    Neuroscience; 2011 May; 181():234-42. PubMed ID: 21277943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease.
    Bretaud S; Lee S; Guo S
    Neurotoxicol Teratol; 2004; 26(6):857-64. PubMed ID: 15451049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
    Schmidt WJ; Alam M
    J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
    Nehru B; Verma R; Khanna P; Sharma SK
    Brain Res; 2008 Mar; 1201():122-7. PubMed ID: 18308296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective effects of indole-3-carbinol on the rotenone rat model of Parkinson's disease: Impact of the SIRT1-AMPK signaling pathway.
    Mohamad KA; El-Naga RN; Wahdan SA
    Toxicol Appl Pharmacol; 2022 Jan; 435():115853. PubMed ID: 34973289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
    Thakur P; Nehru B
    Neuropharmacology; 2014 Apr; 79():190-200. PubMed ID: 24296154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.